Yunhai Biotech Team Wins Second Place in the Final of the 9th Zhongguancun International Frontier Technology Competition

On March 26, the 2026 Zhongguancun Forum Annual Conference – the 9th Zhongguancun International Frontier Technology Competition Final was held at the Zhongguancun International Technology Transfer Center. The Yunhai Biotech Team participated in the final with their project "Development of a miRNA Intelligent Delivery System Based on Framework Nucleic Acids and Exploration of Its Application in Non-invasive Transdermal Drug Delivery" and won the second place.

As a key part of the Zhongguancun Forum Annual Conference, this year's competition, themed "Frontier Leadership, Intelligent Creation of the Future," featured seven major sectors: AI Core Technologies, AI Applications, Innovative Drugs, Medical Devices, New Materials, Cultural Technology, and Financial Technology. It brought together over 2,100 cutting-edge technology projects from more than 68 countries and regions worldwide, with international projects accounting for 43% and AI-related projects accounting for approximately 40%.

Previously, the Yunhai Biotech Team's project stood out among numerous entries in the semifinals, securing a spot in the final. At the final event, ten top-tier projects competed head-to-head in an "8-minute presentation + 60-second scoring" format. A judging panel composed of experts from universities, research institutes, investment institutions, and the industry conducted on-site evaluations to ultimately determine the champion, runner-up, and third-place finisher.

This award represents yet another significant recognition of Yunhai Biotech's innovative explorations in framework nucleic acid delivery technology and non-invasive drug administration. Science and Technology Daily described the project in its coverage as "not a single drug, but a unique drug delivery technology platform," highlighting its platform potential. Beijing Daily also noted in its report that the project focuses on technological breakthroughs addressing the key challenge of nucleic acid delivery, exploring applications aimed at greater efficiency and convenience. Looking at the project itself, "Development of a miRNA Intelligent Delivery System Based on Framework Nucleic Acids and Exploration of Its Application in Non-invasive Transdermal Drug Delivery" focuses on the critical industry challenge of nucleic acid drug delivery, striving to improve delivery efficiency and expand the application boundaries of non-invasive transdermal administration. Public reports suggest that the related technology holds broad potential for future applications in ophthalmic drug delivery, intervention for neurological diseases, and various other scenarios involving nucleic acid drugs and functional molecule delivery, further underscoring the growth potential of Yunhai Biotech as a platform-based technology company.

Recognition is both affirmation and a new starting point. In the future, Yunhai Biotech will continue to be driven by original technological innovation, deepen the development of its universal framework nucleic acid technology platform, persistently achieve breakthroughs in key core technologies and facilitate the translation of results, and accelerate the transition of innovative achievements from the laboratory to industrialization and broader application scenarios, injecting renewed innovative momentum into the high-quality development of the biomedical industry.